BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Arcapta Neohaler: Phase III data

Top-line data from the identical double-blind, placebo-controlled, international Phase III INTRUST 1 and 2 trials in a total of 2,276 patients showed that once-daily 150 µg indacaterol plus once-daily 18 µg Spiriva HandiHaler tiotropium met the primary endpoint of significantly improving FEV1 AUC from 5 minutes to 8 hours post-dose at week 12 vs. Spiriva alone (p<0.001 for...

Read the full 277 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >